PTEN Research
Thomas Pepper is a seasoned professional in clinical development and operations, currently serving as Chief Executive and Director of Clinical Development at PTEN Research since August 2019, where the focus is on advancing research for PTEN Hamartoma Syndrome. Previously, Thomas held the position of Director of Clinical Operations at Alnylam Pharmaceuticals, overseeing multiple global programmes in rare diseases and cardiovascular areas from July 2017 to August 2019. A significant portion of Thomas's career was spent at Roche Pharmaceuticals, culminating as Senior Clinical Program Leader for Oncology, with responsibilities spanning from early-stage drug development to operational delivery for the oncology portfolio. Thomas's experience includes roles at Antisoma and GlaxoSmithKline, along with foundational positions at Roche Pharmaceuticals, and education includes a BSc (Hons) in Natural Sciences from Durham University.
This person is not in any teams
PTEN Research
PTEN Research is a UK-registered charity. We fund and facilitate research that will lead to new and better treatment for PHTS, a rare genetic condition which currently has no health authority approved therapies. We do this by funding PHTS research projects and bringing together a global network of PHTS focused experts and other key partners. PTEN hamartoma tumour syndrome (PHTS) is a rare genetic disease caused by mutations in the PTEN gene. An individual with a PTEN mutation may be diagnosed as having Cowden Syndrome (CS), Bannayan-Riley-Ruvalcaba Syndrome (BRRS), or Autism Spectrum Disorder (ASD) associated with macrocephaly (large head). Together this spectrum of conditions is known as PHTS. Registered charity number: 1173589